By Ethan Covey
A 12-week course of sofosbuvir-ledipasvir (Harvoni, Gilead) is more effective than an eight-week course in patients with HIV and hepatitis C virus (HCV) coinfection, according to a new study.
The findings note a higher probability of relapse in the patients receiving the shorter course of therapy (J Infect Dis 2019 May 15. [Epub ahead of print]).